National Adult Vaccination Program
The National Adult Vaccination Program (NAVP), is a multi-stakeholder industry-supported collaboration to develop a cohesive strategic and policy approach to improve adult vaccination aligned with the recommendations of the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention. The Patient Protection and Affordable Care Act of 2010 included several provisions that emphasize the value of preventive services for older adults, including immunizations. NAVP, to the extent possible, will focus on achieving the Healthy People 2020 immunization goals and such areas as already identified and accepted factors that drive high pediatric immunization rates and translate them to the adult population, adopting a clear adult immunization schedule and driving greater public, provider, and payer awareness of the health benefits of adult immunizations.
NAVP Workgroup
| R. Gordon Douglas, MD NAVP Workgroup Chairperson Weill Cornell Medical College | Paul Etkind, DrPH, MPH National Association of County and City Health Officials | |
| Stefan Gravenstein, MD, MPH NAVP Project Director Warren Alpert Medical School of Brown University Healthcentric Advisors | Walter A. Orenstein, MD Emory University School of Medicine Emory Vaccine Center | |
| Barbara Resnick, PhD, RN, CRNP University of Maryland School of Nursing and School of Medicine | William Schaffner, MD Vanderbilt University School of Medicine The Edward Jenner Society |
NAVP Resources
From Publication to Practice: A Look at Strategies to Improve Immunization Rates for Older Adults
What’s Hot in Immunizations Across the Aging Continuum
From Publication to Practice: An Interdisciplinary Look at New Developments in the Prevention and Treatment of Influenza in Older Adults
Public Policy & Aging Report: Vaccination, Prevention, and Older Adults
Call to Action—Reaching the Healthy People 2020 Goals for Adult Vaccination: Proceedings of the National Adult Vaccination Program Scientific Summit, April 2012
NAVP is developed by GSA and supported by GSK and Merck.
